Do patients with different types of leukemia need to take giritinib (segatan)?

Gilitinib (trade name: Sigmatan) is an oral FLT3tyrosine kinase inhibitor, mainly used to treat FLT3 mutation-positive acute myeloid leukemia (AML) patients. Not all leukemia patients are suitable for taking giritinib, and its use mainly depends on the patient's genetic mutation status. For patients with positive FLT3 gene mutations, giritinib can specifically inhibit the FLT3 signaling pathway, thereby inhibiting leukemia cell proliferation and improving remission rate and survival. Therefore, it has clear clinical application value in this type of patients.

Giritinib has not shown significant benefit in patients with FLT3 wild-type or other types of leukemia, so doctors generally do not recommend the drug for these patients. The type of leukemia needs to be determined through molecular testing or genetic sequencing to ensure targeted and effective medication. If used blindly, it may increase the risk of adverse reactions and fail to obtain therapeutic benefits.

Common side effects of giritinib include bone marrow suppression, fever, abnormal liver function, arrhythmia, and blood pressure fluctuations. Even suitable patients with FLT3 mutations require individualized dose adjustment and monitoring under the guidance of a physician. Doctors usually formulate a reasonable medication plan based on the patient's age, liver and kidney function, blood picture changes, and concomitant medication to ensure efficacy while reducing risks.

Generally speaking, not all patients with leukemia are suitable to take geritinib. Its use is mainly targeted at patients with acute myeloid leukemia who have positive FLT3 mutations. Through genetic testing to clarify the mutation status, doctors can develop individualized treatment plans based on the patient's specific illness and physical conditions. During the treatment process, regular monitoring of blood images, electrocardiograms, liver and kidney function and other indicators is of great significance to ensure safety and efficacy.

Reference materials:https://www.drugs.com/